

ARTICLE OPEN



MECHANISMS OF RESISTANCE

MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia

Laura Mazzer^{1,2}, Manuela Abeltino², Guerino Lombardi¹, Anna Maria Cantoni^{3,15}, Stefano Jottini³, Attilio Corradi³, Micaela Ricca¹, Elena Rossetti^{2,4}, Federico Armando^{5,6}, Angelo Peli⁶, Anna Ferrari⁷, Giovanni Martinelli^{7,8}, Maria Teresa Scupoli⁹, Carlo Visco¹⁰, Massimiliano Bonifacio¹⁰, Alessia Ripamonti^{11,12}, Carlo Gambacorti-Passerini^{11,12}, Antonio Bonati², Roberto Perris^{13,14} and Paolo Lunghi^{13,14}✉

© The Author(s) 2023

Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1/2/BCR::ABL1/BCR/ABL1-driven signaling loop that may determine the efficacy of arsenic trioxide (ATO) in TKI-resistant leukemic patients. We find that activated MEK1/2 assemble into a pentameric complex with BCR::ABL1, BCR and ABL1 to induce phosphorylation of BCR and BCR::ABL1 at Tyr360 and Tyr177, and ABL1, at Thr735 and Tyr412 residues thus provoking loss of BCR's tumor-suppression functions, enhanced oncogenic activity of BCR::ABL1, cytoplasmic retention of ABL1 and consequently drug resistance. Coherently, pharmacological blockade of MEK1/2 induces dissociation of the pentameric MEK1/2/BCR::ABL1/BCR/ABL1 complex and causes a concurrent BCR^{Y360/Y177}, BCR::ABL1^{Y360/Y177} and cytoplasmic ABL1^{Y412/T735} dephosphorylation thereby provoking the rescue of the BCR's anti-oncogenic activities, nuclear accumulation of ABL1 with tumor-suppressive functions and consequently, growth inhibition of the leukemic cells and an ATO sensitization via BCR-MYC and ABL1-p73 signaling axes activation. Additionally, the allosteric activation of nuclear ABL1 was consistently found to enhance the anti-leukemic effects of the MEK1/2 inhibitor Mirdametinib, which when combined with ATO, significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia. These findings highlight the therapeutic potential of MEK1/2-inhibitors/ATO combination for the treatment of TKI-resistant leukemia.

Leukemia; <https://doi.org/10.1038/s41375-023-01940-x>

INTRODUCTION

Despite the clinical success of BCR::ABL1 tyrosine kinase inhibitors (TKIs) therapy for treatment of chronic myeloid leukemia (CML), a substantial number of patients will experience resistance to this pharmacological approach and relapse due to BCR::ABL1-dependent or independent mechanisms [1]. The use of the first-generation TKI drug, Imatinib, and the introduction of more potent the second-generation agents, Dasatinib, Nilotinib and Bosutinib TKIs [1], have improved the 10-year survival of patients newly diagnosed with CML, however none of these agents are active on patients harboring the BCR::ABL1^{T315I} mutation [2].

The third-generation TKI Ponatinib, administered as monotherapy [3] or in combination with other agents [4], remains the only

clinically available drug to overcome the oncogenic effect of the T315I gatekeeper mutation and most of the compound mutations of the oncogenic fusion protein. However, its clinical use is hampered by the serious adverse effects that have been documented [5].

More recently, Asciminib, an allosteric BCR::ABL1 antagonist specifically targeting the ABL1 Myristoyl Pocket (STAMP), has been demonstrated to have superior efficacy compared to Bosutinib and an improved safety profile in patients with CML-CP after at least 2 prior TKIs [6, 7]. Moreover combinations of Asciminib and ATP-competitive TKIs are under clinical investigation [4, 8, 9].

In addition, clinical responses to TKI drugs are short lived in advanced phases of the disease or in Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) [10], and therefore new

¹Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy. ²Department of Medicine and Surgery, University of Parma, Parma, Italy. ³Department of Veterinary Science, University of Parma, Parma, Italy. ⁴National Healthcare Service (SSN—Servizio Sanitario Nazionale) ASL Piacenza, Piacenza, Italy. ⁵University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. ⁶Department for Life Quality Studies Alma Mater Studiorum—University of Bologna, Bologna, Italy. ⁷IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, FC, Italy. ⁸Institute of Hematology "L. e A. Seragnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. ⁹Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. ¹⁰Department of Engineering for Innovation Medicine, Section of Hematology—University of Verona, Verona, Italy. ¹¹Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy. ¹²Adult Hematology, IRCCS San Gerardo, Monza, Italy. ¹³Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy. ¹⁴Centre for Molecular and Translational Oncology—COMT, University of Parma, Parma, Italy. ¹⁵Deceased: Anna Maria Cantoni. ✉email: paolo.lunghi@unipr.it

Received: 20 December 2022 Revised: 10 May 2023 Accepted: 7 June 2023

Published online: 29 June 2023

Table 1. Clinical characteristics of Ph⁺ patients.

	Age at relapse	Disease state	% BM blasts	Received therapy	BCR::ABL1 mutational status	Sokal at diagnosis	BCR::ABL1 transcript type	% BCR::ABL1 at relapse (%IS)
CML#1	ND	Relapse	95	Imatinib	No mutation	ND	ND	ND
CML#2	46	Relapse	70	Dasatinib	No mutation	0.7	b2a2	0.13
CML#3	30	Relapse	>90	Imatinib	T315I	ND	b2a2	ND
CML#4	63	Relapse	>60	Dasatinib	V299L	1.24	e14a2	118.3
CML#5	55	Relapse	80	Imatinib	No mutation	1.35	b2a2	46.5
CML#6	45	Relapse	76	Bosutinib	T315I	ND	b3a2/b2a2	ND
CML#7	45	Relapse	44	Imatinib	F317L	0.66	ND	75.6
CML#8	55	Relapse	35	Ponatinib	No mutation	0.86	ND	ND
CML#9	26	Relapse	23	Dasatinib	No mutation	ND	b2a2	53.9
CML#10	25	Relapse	12	Bosutinib	No mutation	ND	b2a2	90.42
ALL#1 Ph ⁺	75	Relapse	>90	Dasatinib	T315I	ND	e1a2	69.72
ALL#2 Ph ⁺	50	Relapse	>90	Chemotherapy/ Bosutinib	T315A	ND	e1a2	36.45
ALL#3 Ph ⁺	55	Relapse	90	Dasatinib + Steroids/ allo-SCT	T315I	ND	e1a2	ND

treatment strategies are needed for the subset of patients who fail to respond or develop resistance to treatments with these targeted agents.

Arsenic trioxide (ATO), an FDA-approved drug for treatment of acute promyelocytic leukemia [11], also shows a great potential for treatment of other hematologic cancers and solid tumors either as a single agent or in combination therapies [12].

We have previously demonstrated both *in vitro* and *in vivo* that the pharmacological blockade of MEK synergistically potentiates the antitumor effects of ATO in acute myeloid leukemia (AML), CML and multiple myeloma (MM) via activation of multiple apoptotic pathways [13–16].

Based on these our previous findings, we have expanded our investigations on the biological and mechanistic activities of the combination MEK1/2 inhibitors (MEKi) plus ATO in TKIs-resistant Ph⁺ leukemic cells, particularly focusing on the interplay between MEK1/2 and BCR::ABL1, normal ABL1 and normal breakpoint cluster region protein (BCR) kinases.

Notably, leukemia cells expressing BCR::ABL1 oncogenic tyrosine kinase generally also contain the non-translocated *abl* and *bcr* alleles encoding normal ABL1 and BCR kinases that can have tumor suppressive functions, and therefore, play important roles in the pathogenesis of disease and/or in response to therapeutic treatments [17–19].

Our findings reveal a novel oncogenic functional interplay between MEK1/2, ABL1 and BCR signaling kinases, which if pharmacologically disabled by antagonizing MEK1/2 actions renders leukemia cells more responsive to the antitumor agent ATO with consequent implications for the treatment TKI-resistant Ph⁺ leukemias.

MATERIALS AND METHODS

Reagents

Highly specific MEK1/2 inhibitor (MEKi) Mirdametinib (PD0325901; Pfizer Global Research & Development, Ann Arbor, MI). Solid ultrapure arsenic trioxide (As₂O₃; ATO) and the ABL1 allosteric activator 5-[3-(4-fluorophenyl)-1-phenylpyrazol-4-yl] imidazolidine-2,4-dione (DPH) from Sigma-Merck Saint-Louis, MO, USA.

Cell cultures

Imatinib-sensitive Ba/F3p210 wild-type (Ba/F3p210^{WT}) and -resistant Ba/F3p210 mutant lines Ba/F3p210^{Y253F} and Ba/F3p210^{T315I} established from

murine Ba/F3 cells were generated as previously reported [20] and kindly provided by Dr. Michael W. Deininger. Human Ph⁺ Imatinib-resistant cell lines K562-R, LAMA84-R, AR230-R and KCL22-R kindly provided by Dr. Junia V. Melo were generated by exposing parental cell lines to gradually increasing doses of Imatinib and then maintained in 1 μM Imatinib [21]. The experiments on these cell lines were performed in fresh media after Imatinib washout. CML cell lines (10⁵ cells/ml) were seeded in fresh RPMI 1640 (Sigma-Merck) supplemented with 10% fetal bovine serum (FBS) (Sigma-Merck), 2 mM L-glutamine and penicillin G (100 U/ml)/streptomycin (100 mg/ml) (Sigma-Merck) in the presence of DMSO (vehicle) or PD325901 (0.5 μM) for 3 h and then were incubated with ATO at 2 μM or DPH at 10 μM. Human Ph⁺ ALL acute lymphoblastic leukemia cell line SUP-B15 [22] kindly provided by IZSLER biobank was from ATCC, maintained in IMDM medium (Sigma-Merck) supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine and penicillin G (100 U/ml)/streptomycin (100 mg/ml) and treated as described for CML cells.

Supplementary Table 1 shows the IC50 values for Imatinib in the Imatinib-resistant cell lines used. Human bone marrow-derived stromal cell line HS-5 was from ATCC (Manassas, VA, USA), murine stromal cell line MS-5 and NB4 acute leukemia cell line were from DSMZ (Braunschweig, Germany).

Freshly isolated or cryopreserved bone marrow or peripheral blood cells from 10 CML and 3 ALL Ph⁺ patients at relapse were taken in accordance with the Declaration of Helsinki. The study was approved by local Ethical Authority (012/2009/U/Tess, Bologna; n. 145/2014, Parma; n. 1828/2010, Verona; n. 943/2006, Milano). Primary Leukemia blasts were separated on a Ficoll-Hypaque density gradient. Patient characteristics are reported in Table 1. For samples with percentage of blasts less than 90%, leukemia blasts were enriched to >90% by immunomagnetic sorting using anti-CD34 beads (Miltenyi Biotec) before the treatments as we previously described [23].


Freshly isolated or cryopreserved/thawed CD34⁺ leukemia blasts (2.5 × 10⁵ cells/ml) were seeded in complete IMDM medium and treated as described for cell lines.

Apoptosis assays, siRNA and plasmid transfections, molecular, immunocytochemistry and statistical analysis

These methods have been previously published [13–16] and are described in the Online Supplementary Methods.

Animal studies

Protocols for animal experimentation were approved by the University of Parma Ethics Committee and by the Italian Ministry of Health. Animal Treatment Protocols, histological and immunohistochemical procedures are described in detail in the Online Supplementary Methods.



RESULTS

MEK1/2 inhibition synergizes with ATO to induce cytotoxicity in TKIs-resistant Ph⁺ leukemic cells

We first analyzed the pharmacologic interactions between the MEKi Mirdametinin (PD0325901; indicated as PD) and ATO using a

fixed-ratio experimental design on Ph⁺ leukemia cell lines displaying different degrees of resistance to the first, second, and third generation of BCR::ABL1 TKIs [20, 21].

Combined treatment of cells with PD plus ATO resulted in the synergistic induction of apoptosis in all the tested cell lines,

Fig. 1 Pharmacological blockade of MEK1/2 synergistically potentiates the cytotoxic effects of ATO in TKI-resistant Ph⁺ leukemia. **A** Imatinib-sensitive and -resistant cell lines were treated sequentially with escalating doses of PD0325901 (0.2–2 μM) for 3 h and subsequently with ATO (0.5–5 μM) alone or in combination at the constant molar ratio of 1:2 and after 48 h cell death was measured by Annexin V-FITC/PI labeling; Combination index Plots (fa-CI) were generated using the Chou-Talalay method and the Calcsyn software. Mean Combination Index values (CI) \pm SD was estimated from CI at ED50, ED75 and ED90 values of the combination PD + ATO. CI values $<$ 1 indicate synergism, CI value = 1 indicate additive effect and CI values $>$ 1 indicate antagonistic effect. **B** Relative levels of cell death were measured by Annexin V-PE/7-AAD labeling in Imatinib-resistant cell lines and the murine Ba/F3p210^{T3151} cells after 48 h of treatment with PD0325901 and ATO in absence or presence of a stromal feeder layer of either human, HS-5/GFP (+HS-5), or murine origin, MS-5/GFP (+MS-5; see Supplementary Methods). Values represent means \pm SD of three independent experiments. (* p $<$ 0.01 and # p $<$ 0.02 vs. either treatment alone; ° p $<$ 0.05 ATO + HS-5 vs. ATO; Dunnett test). **C** Relative levels of cell death measured in primary cells from 10 CML and 3 ALL Ph⁺ patients grown in the presence or absence of HS-5 cells after 24 h of treatment with PD0325901 and ATO as in (B). Median line in box plots is delimited by the 25th and 75th percentiles; (* p $<$ 0.001 PD + ATO vs. either treatment alone; Dunnett test). Imatinib-resistant CML cell lines (**D**) and primary leukemic cells from patients with Ph⁺ CML (**E**) (CML#4, #5, #6, #7, #9) were growing in semi-solid methylcellulose medium (10³ cells/ml) in presence of PD0325901 (0.5 μM), ATO (1 μM for CML cell lines, 0.5 μM for primary samples) or the combination PD + ATO. Live colonies were detected after 10 days (CML cell lines) or 14 days (primary samples) of culture by MTT (1 mg/ml) staining and counted using ImageJ quantification software. Data are expressed as percent of colony numbers. The results are the means \pm SD of three different measurements performed in triplicate (* p $<$ 0.01, Dunnett test).

regardless of their sensitivity to TKIs (Fig. 1A and Supplementary Fig. 1A).

Attachment of leukemia cells to the stroma-derived cell lines HS-5 (human) or MS-5 (murine) conferred a significant protection against ATO-induced cell death in three out of the six tested cell lines (LAMA84-R, AR230-R and SUP-B15), but this protective effect was abrogated by the pharmacological inhibition of MEK1/2 (Fig. 1B).

Consistent with observations on leukemic cell lines, PD significantly increased ATO-induced cell death in TKI-resistant primary blasts derived from patients with CML or ALL harboring native or mutated BCR::ABL1 (p $<$ 0.001; n = 13), when treated either in the presence or absence of the stromal HS-5 cell line (Fig. 1C, Supplementary Fig. 1B and Table 1).

These findings highlighted a clear connection between loss-of-function of MEK1/2 and ATO sensitivity that may be independent of the microenvironment.

Finally, combination of PD and ATO significantly reduced the clonogenic potential of TKIs-resistant Ph⁺ cell lines and primary CML CD34⁺ cells, as compared to either agent alone (Fig. 1D, E and Supplementary Fig. 2).

MEK1/2 regulate the activity and subcellular localization of ABL1 in Ph⁺ leukemic cells

Previous studies have shown that ATO activates ERK1/2 and their associated pathways in leukemic cells [14, 15, 24]. We therefore tested if this was also the case for the TKIs-resistant Ph⁺ leukemic cells. ATO enhanced ERK1/2 activity in four out of the six tested cell lines (BaF3^{p210T3151}, K562-R, KCL22-R and SUP-B15) and in four out of the five primary-derived leukemic samples (except for ALL#1), while PD treatment of the cells reduced the basal phosphorylation status of ERK1/2 and blunted the further activation of these kinases in response to ATO in all the analyzed samples (Fig. 2A).

Then, in order to investigate the molecular mechanisms by which PD enhanced the cell death-inducing potential of ATO in the TKIs-resistant Ph⁺ leukemic cells we first evaluated whether PD and/or ATO treatments affected the expression and activity of the BCR::ABL1 oncoprotein and its downstream direct substrate CrkL, an adapter protein commonly used as read-out for the BCR::ABL1 and ABL1/2 activities [18, 25]. Interestingly, although either treatment failed to substantially affect the expression and activity of BCR::ABL1 in the majority of the leukemia cell lines and patient-derived leukemic blasts, we observed that treatment with PD reduced to a different extent the basal tyrosine phosphorylation levels of ABL1 (Y412) and CrkL (Y207) (Fig. 2A and Supplementary Fig. 3), and/or blunted the phosphorylation of these proteins in response to ATO in most of tested samples; this was true with the exception of the KCL22-R and SUP-B15 cell lines in which MEK1/2 inhibition did not negatively modulate ABL1^{Y412}

phosphorylation despite reducing that of CrkL^{Y207} and CML#3 in which MEK1/2 inhibition did not modulate neither ABL1^{Y412} nor CrkL^{Y207} phosphorylations (Fig. 2A).

Moreover, as predictable, drug treatments did not substantially alter CrkL^{Y207} phosphorylation in LAMA84-R and AR230-R leukemia cell lines lacking *abl* gene expression [21] (Fig. 2A).

As ABL1 may exhibit both pro- and anti-apoptotic functions depending on its nuclear vs. cytoplasmic localization [18, 19, 26, 27] and its intracellular localization is regulated by phosphorylation of its Thr735 residue which promotes cytoplasmic sequestration by the 14-3-3 protein [28], we explored whether MEK1/2 inhibition also affected Thr735 phosphorylation and/or the subcellular localization of ABL1 in leukemia cells.

MEK1/2 inhibition significantly decreased the basal ABL1^{T735} phosphorylation status and/or blunted the ATO-induced Thr735 phosphorylation of ABL1 in the four leukemic cell lines expressing wild-type ABL1 and in patient-derived leukemic blasts but failed to produce any effect in LAMA84-R and AR230-R (Fig. 2A).


The stronger Thr735 phosphorylation of ABL1 observed after ATO compared to control treatment correlated well with the accumulation of the kinase in the cytoplasm and, consequently, with the reduction of its nucleus-to-cytoplasm (N/C) ratio observed in ATO-treated vs. other treatments (Fig. 2B). Conversely, PD treatment either alone or in combination with ATO caused a significant translocation of ABL1 from the cytoplasm to nucleus, thereby elevating its N/C ratio as compared to control or ATO treatments (Fig. 2B), a result that was further confirmed by immunocytochemistry analysis (Fig. 2Ci).

Because the different drugs treatments regulated the shuttling between the nucleus and the cytoplasm of the ABL1 but not that of BCR::ABL1 kinase (Fig. 2Cii), we were able to confirm that the shuttling protein kinase that accumulates in the nucleus or in the cytoplasm in response to the various treatments was indeed ABL1 kinase (Fig. 2Ci).

Furthermore, upon MEK1/2 inhibition the levels of the Y412 phosphorylated forms of ABL1 were drastically reduced in the cytoplasm while being increased in the nucleus (Fig. 2B); the opposite effects on ABL1^{Y412} phosphorylation caused by PD in the two subcellular compartments can partly explain the relatively lower fold reduction in ABL1^{Y412} phosphorylation observed in whole-cell vs. cytoplasmic extracts derived from the same cancer cell samples exposed to PD treatment (Fig. 2A, B).

Activation of normal ABL1 kinase enhances the efficacy of MEK1/2 inhibitor PD0325901 in leukemia cells expressing oncogenic ABL1 kinase mutants

Given that MEK1/2 inhibition caused nuclear accumulation of endogenous phospho-ABL1^{Y412} we hypothesized that an increased stimulation of nuclear ABL1 activity may potentiate the antitumor



effects of PD in TKIs-resistant Ph⁺ leukemic cells. As may have been expected, administration of the ABL1 allosteric activator, DPH [29], to PD pre-treated leukemia cells significantly enhanced the cytostatic and/or cytotoxic effects of the MEKi in leukemic cell lines containing wild-type *abl* allele, but not in cells lacking this allele (Fig. 3Ai, ii). In analogy to what was observed in leukemic cell lines, we found that DPH significantly ($p < 0.001$; $n = 9$) increased PD-induced cell death in primary leukemic cells from patients clinically resistant to TKIs (Fig. 3Aii and Supplementary Fig. 4).

Furthermore, the combined treatment of PD and DPH significantly decreased the clonogenic potential of either TKIs resistant CML cell lines, or primary leukemic cells, when compared to either mono-treatment (Fig. 3Bi, ii and Supplementary Fig. 5).

Finally, we also found that in NB4 cells, a non-CML/BCR::ABL1-negative myeloid leukemia cell line expressing wild-type ABL1, MEK1/2 blockade induced a nuclear accumulation of ABL1 (Fig. 3C) and that the ABL1 allosteric activator DPH significantly increased the anti-leukemic effects of PD (Fig. 3Ai, ii).

Fig. 2 MEK1/2 impact on the activity and subcellular localization of ABL1 kinase in TKI-resistant Ph+ leukemia. **A** Western blot analysis of endogenous phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-BCR::ABL1 (Tyr412), BCR::ABL1, phospho-ABL1 (Tyr412), phospho-ABL1 (Thr735), ABL1, phospho-CrkL (Tyr207), CrkL and Actin in Ba/F3p210^{T3151}, Imatinib-resistant Ph+ cell lines and primary cells derived from patients with Ph+ leukemia following 24 h of treatment with PD0325901 (0.5 μ M) and ATO (2 μ M), alone or in combination. The horizontal arrowheads indicate the position of the 200 kDa protein marker for Ph+ ALL cell line and primary blasts from Ph+ ALL patients. Phospho-BCR::ABL1 (Tyr412) and phospho-ABL1 (Tyr412), BCR::ABL1 and ABL1 are from the same blot. Revealed bands were subjected to densitometric scanning and the ratio of each protein to Actin loading control was calculated. Levels of phosphorylated proteins were normalized to total expression levels. The relative fold change of protein levels was normalized with respect to the level of the untreated control, which was taken as 1. The histograms below represent the mean \pm SD of four independent experiments on Ph+ cell lines and of $n = 5$ primary samples ($^{\circ}p < 0.05$, $^*p < 0.01$, vs. untreated control, Dunnett's test). **B** Immunoblotting for phospho-ABL1 (Tyr412) and ABL1 using Tubulin β and Lamin A/C as loading controls, on cytoplasmic (cyto) and nuclear (nucl) lysates of Ba/F3p210^{T3151}, K562-R, KCL22-R and primary cells from Ph+ leukemia patients that had been sequentially treated with PD0325901 (0.5 μ M) and ATO (2 μ M) alone or in combination for 24 h. Bands were subjected to densitometric scanning: cytoplasmic and nuclear blots were normalized to total Tubulin β and Lamin A/C respectively. The relative fold change of cytoplasmic or nuclear ABL1 and phospho-ABL1 (Tyr412) level was normalized with respect to control condition, which was taken as 1. The ratio of nuclear to cytoplasmic ABL1 and phospho-ABL1 (Tyr412) protein expression (Nucl/Cyto) is shown. In histogram are shown average quantification results \pm SD of three independent blots on Ph+ cell lines and of $n = 3$ primary samples ($^{\circ}p < 0.05$, $^*p < 0.01$, Dunnett's test). **C** Immunocytochemistry (i) and Western blot (ii) analysis of K562-R cells treated with PD0325901 (0.5 μ M) and/or ATO (2 μ M) for 24 h. (i) Immunocytochemistry staining of ABL1 (Red) and DAPI (blue) for nuclear staining. The microphotographs are representative of similar observation in three independent experiments. (ii) Whole-cell lysates and nuclear extracts of PD and/or ATO-treated K562-R immunoblotted for BCR::ABL1, ABL1, Tubulin β and Lamin A/C as loading controls. Bands from nuclear extracts were subjected to densitometric scanning and normalized to Lamin A/C expression. ABL1 protein expression under control conditions was set as 1 for comparison and is shown below the blot.

These observations would support the hypothesis that the putative function of MEK1/2 as regulators of subcellular localization and nuclear trafficking of ABL1 is common among the different types of leukemia and is BCR::ABL1 independent.

MEK1/2 physically and functionally interact with normal BCR and ABL1 protein kinases in TKIs-resistant Ph+ leukemic cells

Since phosphorylation at Y360 and Y177 residues by both ABL1 and BCR::ABL1 disables the anti-oncogenic activity of the p160 BCR normal protein [30–33] we explored whether the pharmacological blockade of MEK/ERK signal transduction pathway impacting on the activity and subcellular localization of ABL1 would secondarily affect the tyrosine phosphorylation of p160 BCR.

Compared to control, we found that MEK1/2 inhibition significantly reduced Y360 and/or Y177 phosphorylation of p160 BCR in all the four leukemic lines encoding normal ABL1 kinase and in patient-derived leukemic blasts (Fig. 4A).

Treatment with ATO, differentially increased the basal phosphorylation of Y360 BCR in Ba/F3p210^{T3151}, K562-R and LAMA84-R cell lines and in four out of the five primary-derived leukemic samples and Y177 BCR in Ba/F3p210^{T3151} cell line and CML#1 and CML#3 patient-derived primary samples. By contrast pretreatment with PD prevented these increments (Fig. 4A).

Consistently with the fact that dephosphorylation of BCR at Y360 residue is critical for its transphosphorylation kinase activity [30–33] and that, once activated the kinase exerts its anti-oncogenic effects by reducing c-Myc stability in BCR::ABL1-positive cells [34], we observed that the inhibition of MEK1/2 by PD led to a decrease in c-Myc protein expression in all but two samples analyzed. Finally, treatment with PD, either alone or in combination with ATO, also caused decreased Y360 phosphorylation of BCR::ABL1 in all the samples analyzed and Y177 residue in 6 out of the 11 samples analyzed (except for K562-R, LAMA84-R, ARR230-R, SUP-B15 and ALL#2) (Fig. 4A and Supplementary Fig. 6).

To then better understand the interplays between MEK1/2, BCR::ABL1, non-mutated ABL1 and BCR we ectopically expressed a constitutively active form of MEK1 (ca)MEK1 (MEK1S218D/S222D) in K562 cells displaying a close to 3-fold lower basal MEK1/2 activity than K562-R [35] (Supplementary Fig. 7) and assessed whether this manipulation affected the phosphorylation pattern of the mutated oncogenic and non-mutated counterparts, and the leukemic cells' responsiveness to ATO. We found that the ectopic expression of (ca)MEK1 caused enhanced phosphorylation of not only the MEK1/2 preferred substrates ERK1/2 [36], but also of BCR::ABL1^{Y177/Y360} and ABL1^{Y412/T735} and their direct substrates BCR^{Y177/Y360} and CrkL^{Y207} (Fig. 4B).

Conversely, siRNA knockdown of MEK1/2 in these (ca)MEK1-overexpressing cells consistently attenuated the enhanced phosphorylations (Fig. 4B).

In accordance with the fact that MEK1 can elicit pro-survival signals in the leukemia cells we also found that (ca)MEK1-overexpressing cells were less sensitive to ATO-induced cell death as compared to vector control transfected cells and that genetic disruption of MEK1/2 functions in these (ca)MEK1-overexpressing cells was able to restore their responsiveness to ATO (Fig. 4Ci, Cii and Supplementary Fig. 8).


The fact that genetic and/or pharmacological perturbation of MEK1/2 affected ABL1 and BCR activities suggested that either MEK1/2 or their downstream substrates could be directly responsible for the phosphorylation events in these two kinases. Reciprocal co-immunoprecipitation analysis showed that MEK1/2 were associated with BCR::ABL1, BCR and ABL1, and that these associations were abrogated upon the pharmacological blockade of MEK1/2 (Fig. 4D).

All together these findings demonstrate that MEK1/2 can effectively enhance the oncogenic potential of BCR::ABL1 either by directly phosphorylating the fusion oncoprotein at the Y360 and/or Y177 residues [33, 37, 38] or by phosphorylating at the same Tyr residues, and therefore inactivating, its non-mutated counterpart BCR exhibiting tumor-suppressive activities against BCR::ABL1 [30–34].

Then, to rule out the possibility that the oncoprotein protein BCR::ABL1 could act as a bridging adapter molecule for connecting MEK1/2 to ABL1 and/or BCR kinases, we performed parallel co-immunoprecipitation experiments using the BCR::ABL1-negative NB4 leukemia cells. We found that, under basal conditions, MEK1/2 form complexed with BCR and ABL1 and that such tetrameric complexes are susceptible to pharmacological blockade of MEK1/2 function also in the absence of BCR::ABL1 (Fig. 4Ei). Moreover, similarly to what we observed in the BCR::ABL1-positive leukemic cells, blockade of MEK1/2 caused BCR^{Y360/Y177} and ABL1^{T735/Y412} dephosphorylation in the BCR::ABL1-negative NB4 cell line (Fig. 4Eii). Collectively, these findings suggest that the physical and functional interplays between MEK1/2, BCR and ABL1 kinases ensue in a BCR::ABL1-independent manner.

MEK1/2 inhibitor PD0325901 plus ATO combination acts through the ABL1-p73-P53AIP1 signaling axis to induce apoptosis in TKI-resistant Ph+ leukemic cells

Since nuclear ABL1 is capable of activating and stabilizing endogenous p73 in response to various DNA-damaging agents including ATO [13, 15, 16, 39, 40] and our previous studies



demonstrated the involvement of the p73 pathway in the cytostatic and/or cytotoxic effects exerted by PD and/or ATO treatments on AML, CML and MM cells [13, 15, 16], we sought to determine whether p73 is a molecular target of the combined treatment also in TKIs-resistant BCR::ABL1 leukemic cells.

The p73 protein (a paralogue of the p53 tumor suppressor), widely known to regulate several p53 target genes including p21, Bax, and p53-regulated apoptosis inducing protein 1 (p53AIP1), is translated as multiple transactivation competent (TA) pro-apoptotic and anti-proliferative COOH-terminal splicing isoforms

Fig. 3 Activation of native ABL1 kinase enhances the efficacy of MEK1/2 inhibitor PD0325901 in leukemia cells expressing oncogenic ABL1 kinase mutants. **A** (i–ii) Imatinib-resistant Ph+ cell lines as well as murine Ba/F3p210^{T3151} were incubated with PD0325901 (0.5 μM) and subsequently with the ABL1 activator DPH (10 μM). After 48 h, cell proliferation was evaluated by counting the total number of viable cells and cell death was measured by Annexin V-FITC/PI labeling. Both cytostatic (i) and cytotoxic (ii) effects of PD/DPH treatment on Ph+ leukemia cells were compared with BCR::ABL1-negative leukemia cell line NB4. Values represent means ± SD of three independent experiments. (^o*p* < 0.005 and **p* < 0.001 vs. either treatment alone; Tukey–Kramer tests). (iii) Analogous analyses performed on primary leukemic cells from 7 CML and 2 Ph+ ALL patients treated with PD0325901 (0.5 μM) and DPH (10 μM). After 24 h cell death was measured by Annexin V-FITC/PI staining or sub-G1 DNA content. Median line in box delimited by 25th and 75th percentiles (**p* < 0.001 vs. either treatment alone; Dunnett test). **B** K562-R and KCL22-R cells (i) and primary leukemic cells from patients with Ph+ CML (ii) (CML#4, #5, #6, #7, #9) were seeded in semi-solid methylcellulose medium (10³ cells/ml) in presence of PD0325901 (0.5 μM), DPH (10 μM) or the combination PD + DPH. Live colonies were detected after 10 days (CML cell lines) or 14 days (primary samples) of culture by MTT (1 mg/ml) staining and counted using ImageJ quantification software. Data are expressed as percent of colony numbers. The results are the means ± SD of three different measurements performed in triplicate (**p* < 0.01, Dunnett test). **C** Immunoblotting for ABL1, Tubulin β and Lamin A/C as loading controls on cytoplasmic (cyto) and nuclear (nucl) lysates of BCR::ABL1-negative leukemia cells NB4 treated with PD0325901 (0.5 μM) for 24 h. The relative fold change of cytoplasmic or nuclear ABL1 was normalized with respect to control condition, which was set as 1. The ratio of nuclear to cytoplasmic ABL1 protein expression (Nucl/Cyto) is shown as average quantifications ± SD of three independent blots (^o*p* < 0.02, **p* < 0.001, vs. untreated control cells, Dunnett's test).

(α, β, γ, δ, ε, ζ) of which the two predominant forms are p73 α and p73β [41]. In addition, dominant-negative (ΔN) p73 variants expressed from a second promoter, lack the amino-terminal transactivation domain, act as trans-repressors of p53- and p73-dependent transcription, and have anti-apoptotic and pro-proliferative potential [41]. The balance between TA and ΔN-p73, or their relative ratio, is important in cancer and in the response to chemotherapy. We therefore evaluated the TA-p73α, TA-p73β and ΔN-p73 relative expression levels in leukemia cells and then assessed the TA/ΔN-p73 ratio.

PD mono-treatment increased the ratio of TA/ΔN-p73 by either elevating TA-p73 and/or reducing ΔN-p73 in all but one of the 10 samples examined. ATO single treatment elevated TA/ΔN-p73 ratio in 7 out of the 10 samples analyzed. However, either of the single treatments were less efficient in affecting the TA/ΔN-p73 ratio as compared to the PD/ATO combined treatment except for ALL#2 (Fig. 5A). Because p73 isoforms are subjected to specific posttranslational modifications that stabilize and induce the transactivation function of TA-p73 [13, 39–41] we also evaluated whether PD and/or ATO treatments modulated the Y99 phosphorylation and/or the K321 acetylation states of p73, the two posttranslational modifications, induced by activated ABL1 and acetyltransferase p300 respectively, that are known to boost the anti-proliferative and/or pro-apoptotic transcriptional activities of TA-p73 isoforms [39–41].

Compared to the control, treatment with PD increased the nuclear levels of phospho-Y99 p73 in TKI-resistant cell lines encoding normal ABL1 kinase and in all patient-derived blast samples examined, whereas ATO either alone or in combination with PD preferentially caused nuclear accumulation of acetylated p73^{K321} (Fig. 5B). Accordingly, combined PD/ATO treatment could be demonstrated to consistently increase the levels of phospho-acetylated TA-p73^{Y99/K321}.

Given that these specific posttranslational modifications events bolster p73 apoptotic functions by potentiating the selective recruitment of p73 onto the promoters of apoptotic target genes vs. gene involved in cell cycle arrest and re-entry [13, 15, 16, 39–41], we examined the effects of the drug treatments on the expression levels of p53AIP1, Bax, Bak, Puma, Noxa and Bim, all known to be established p53/p73 pro-apoptotic target genes [16, 41, 42].

We found that treatment with PD increased the levels of Bim, whose stability is also post-transcriptionally regulated by ERK [43], in all the cell samples analyzed, while it decreased the basal levels of NOXA, except in SUP-B15 cell line. PD treatment was also able to decrease the basal levels of Bax, Bak and/or PUMA although to a different extent across the cell samples examined (Fig. 5C).

ATO alone, and to a lesser extent when used in combination with PD, increased the levels of Bax, Bak, PUMA and/or NOXA as

compared to control in all the cell samples analyzed, whereas the combined treatment with the two agents upregulated p53AIP1 in Ba/F3p210^{T3151}, K562-R, KCL22-R, AR230-R and SUP-B15 cell lines and in all the analyzed patient samples. Moreover, the combined treatment increased the levels of Bak protein as compared to single treatments in KCL22-R and in ALL#1 leukemic cells (Fig. 5C).

As predictable, increased levels of Bim, alongside augmented expression of p53AIP1 and/or Bak correlated well with the enhanced Caspase-3 and PARP cleavage observed in the leukemia cells treated with the combination of PD and ATO (Fig. 5C). In agreement with the biochemical findings indicating the activation of the mitochondrial apoptotic pathway, we also found that combined treatment with PD and ATO strikingly potentiated the loss of Δψ_m induced by ATO alone in both primary leukemia blasts (Fig. 5D) and leukemia cells lines (Supplementary Fig. 9). Finally, to determine the biologic relevance of the p73 pathway in mediating PD/ATO-induced apoptosis, the endogenous TA-p73 or ΔN-p73 transcripts were selectively knocked-down in Ba/F3p210^{T3151} and K562-R cells through specific siRNA probes. We found that loss of TA-p73 significantly attenuated, whereas loss of ΔN-p73 significantly enhanced, the cell death induced by ATO and/or PD/ATO treatments (Fig. 5E).

Pharmacological blockade of MEK1/2 agonizes the anti-leukemic effect of ATO in vivo

To assess the in vivo therapeutic efficacy of combining MEKi Mirdametinib (PD0325901) and ATO treatments we tested the effect of these drugs in a mouse model of TKI-resistant, BCR::ABL1-dependent disease. We found that animal survival was significantly improved in mice treated with the combination PD/ATO vs. those that received monotherapies or Imatinib or vehicle alone (*p* < 0.0015) (Fig. 6A). Consistently with these results, mice treated for 20 days with vehicle, PD, ATO or Imatinib exhibited more pronounced hepatosplenomegaly as compared to those treated with PD/ATO combination (Fig. 6B). Moreover, histopathological analysis consistently revealed a massive infiltration of leukemic cells in the livers and spleens of vehicle or Imatinib-treated mice but not in those from PD/ATO-treated mice that displayed markedly reduced tumor cell infiltration and retained their normal tissue architecture of these organs (Fig. 6C).

Immunohistochemical analyses of liver and spleen sections from PD/ATO-treated animals also revealed a significant reduction in the frequency of Ki67-positive cells and increased frequency of leukemic cells with activated Caspase-3, when compared to that seen in the organs of animals treated with vehicle or Imatinib (Fig. 6C). This observation was in agreement with the reduction in disease burden and the improved survival rate observed in mice treated with the PD/ATO combination therapy.





Fig. 4 MEK1/2 functionally interact with normal BCR and ABL1 in TKI-resistant Ph⁺ leukemia cells. **A** Analysis of endogenous phospho-BCR::ABL1 (Tyr360) and (Tyr177), BCR::ABL1, phospho-BCR (Tyr360) and (Tyr177), BCR, c-Myc and Actin as loading control in murine Ba/F3p210^{T3151} cells, Imatinib-resistant Ph⁺ leukemia cell lines and primary cells from Ph⁺ leukemia patients following 24 h of sequential and combined treatment with PD0325901 (0.5 μM) and ATO (2 μM). The horizontal arrowheads indicate the position of the 200 kDa protein marker for Ph⁺ ALL cell line and primary blasts from Ph⁺ ALL patients. The graphs show the relative fold change of phospho-BCR (Tyr360) and (Tyr177) normalized to total BCR and c-Myc normalized to Actin expression. Phospho-BCR::ABL1 (Tyr360) and phospho-BCR (Tyr360), Phospho-BCR::ABL1 (Tyr177) and phospho-BCR (Tyr177), BCR::ABL1 and BCR are from the same blot. Phosphorylation status of BCR and c-Myc expression under control conditions were set as 1 for comparison and are shown in the histograms (mean ± SD of three independent blots of Ph⁺ cell lines and of n = 5 primary samples; *p < 0.05, **p < 0.01, ***p < 0.005, vs. untreated control cells; Dunnett test). **B** K562 cells expressing empty vector control (EV) or constitutive-active form of MEK1 (ca-MEK) were subjected to Western Blot analysis to monitor the expression of phospho-MEK1/2 (Ser217/221), MEK1/2, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-BCR::ABL1 (Tyr412), phospho-BCR::ABL1 (Tyr360), phospho-BCR::ABL1 (Tyr177), BCR::ABL1, phospho-ABL1 (Tyr412), phospho-ABL1 (Thr735), ABL1, phospho-BCR (Tyr360) and (Tyr177), BCR, phospho-CrkL (Tyr207), CrkL and Actin. K562-(ca)MEK cells were then electroporated with control siRNA or with MEK1/2 siRNA and after 24 h total cell lysates were subjected to western blot analysis of the same panel of proteins described above in panel. **C** (i) Relative levels of apoptosis revealed in stable clones of K562 cells transfected with empty vector (EV) or with plasmid expressing Activated MEK1 [(ca)MEK] after 72 h of ATO (2 and 4 μM) treatment. (ii) Relative levels of apoptotic cell death in K562-(ca)MEK cells subjected to the ATO (2 μM) treatments following siRNA knockdown of MEK1/2 or transfection with a non-targeting control siRNA (Cont), as determined by flow cytometric analysis of sub-G1 DNA content. **D** K562-R cell line was treated with PD0325901 (0.5 μM) and after 24 h of treatment subjected to immunoprecipitation (IP) using anti-BCR antibody or anti-MEK 1/2 antibody or control antibody (IgG) and immunoblotted with anti-BCR and anti-MEK1/2 antibodies. In the same way K562-R lysates were subjected also to immunoprecipitation (IP) using anti-ABL1 antibody or anti-MEK 1/2 antibody or control antibody (IgG) and immunoblotted with anti-ABL1 and anti-MEK1/2 antibodies. For comparison, cell lysates from K562-R cells were loaded in the same gel. **E** (i) NB4 acute leukemia cell line was treated with PD0325901 (0.5 μM) and after 24 h subjected to immunoprecipitation (IP) using anti-BCR antibody or anti-ABL1 antibody, anti-MEK 1/2 antibody or control antibody (IgG) and immunoblotted against BCR, ABL1 and MEK1/2. (ii) The same cell lysates were immunoblotted against phospho-BCR (Tyr360), phospho-BCR (Tyr177), phospho-ABL1 (Tyr412), phospho-ABL1 (Thr735), phospho-ERK1/2 (Thr202/Tyr204) and Tubulin β as loading control. Western blot results were subjected to densitometric scanning and normalized to Tubulin β expression. Protein expression under control conditions was set as 1 for comparison and is shown below the blots.



MEK1/2 inhibitor PD0325901 and ATO combination activates normal BCR and ABL1 tumor-suppressor functions in vivo

The histopathological data shown in Fig. 6B, C were supported by immunoblotting analysis of the lysates from livers and spleens showing a marked expression of BCR::ABL1 in mice treated with

Imatinib or vehicle, but not in mice treated with the PD/ATO drug combination (Fig. 7A and Supplementary Fig. 10A).

Additional molecular and immunohistochemical analyses on spleen and/or liver lysates and sections confirmed in vivo the decreased p-ABL1 (T735), p-CrkL (Y207), p-BCR (Y360), p-BCR

Fig. 5 Combined treatment with MEK1/2 inhibitor PD0325901 and ATO activates the p73 pathway in TKI-resistant Ph+ leukemia cells. **A** Analysis of endogenous TA-p73 $\alpha + \beta$, Δ N-p73 and Actin expression in murine Ba/F3p210^{T3151} cells, Imatinib-resistant Ph+ cell lines and primary cells from Ph+ leukemia patients following sequential and combined treatment with PD0325901 (0.5 μ M) and ATO (2 μ M) for 24 h. TA-p73 $\alpha + \beta$ and Δ N-p73 were analyzed sequentially and images shown are from the same blot. The graphs show the relative fold change of TA-p73 $\alpha + \beta$, Δ N-p73 and the ratio TA/ Δ N-p73 normalized with respect to control condition, which was set at 1 (mean \pm SD of three independent blots of Ph+ cell lines and of $n = 4$ primary samples; $^{\circ}p < 0.05$, $^{*}p < 0.005$ vs. untreated control cells, Dunnett test). **B** Analysis of phospho-p73 (Tyr99) and acetyl-p73 (Lys321) levels in nuclear extract of murine Ba/F3p210^{T3151} cells, Imatinib-resistant Ph+ cell lines and primary cells from Ph+ leukemia patients following sequential and combined treatment with PD0325901 (0.5 μ M) and ATO (2 μ M) for 24 h. Bands from nuclear extracts were subjected to densitometric scanning and normalized to Lamin A/C expression. The graphs show the fold changes of phospho-p73 (Tyr99) and acetyl-p73 (Lys321) in nuclear extracts, relative to control conditions set at 1 (mean \pm SD of three independent blots of Ph+ cell lines and of $n = 4$ primary samples; $^{\circ}p < 0.05$, $^{*}p < 0.01$ vs. untreated control cells, Dunnett test). **C** Relative expression levels of endogenous p53AIP1, Bax, Bak, PUMA, NOXA, Bim_{EL}, cleaved Caspase-3 and cleaved-PARP in cells treated as described in (A, B). Western blot results were subjected to densitometric scanning and normalized to Actin expression. Protein expression under control conditions was set as 1 for comparison and is shown below the blots. **D** Loss of mitochondrial membrane potential ($\Delta\Psi$ m) as determined by flow cytometry in primary blasts from patient ALL#2 after 24 h of treatment with PD0325901 (0.5 μ M) and/or ATO (2 μ M) or Imatinib (1 μ M). **E** Relative levels of cell death in Ba/F3p210^{T3151} cells and K562-R cells subjected to the above drug treatments following siRNA knockdown of TA-p73 or Δ N-p73 or transfection with a non-targeting control siRNA (Control), as determined by flow cytometric analysis of Annexin V-FITC/PI staining. Values represent means \pm SD of three independent experiments ($^{*}p < 0.02$, $^{#}p < 0.05$ TA-p73 or Δ N-p73 siRNA condition vs. control siRNA condition, Tukey–Kramer tests). Transfected cells were subjected to western blot analysis to monitor TA-p73 $\alpha + \beta$ or Δ N-p73 silencing.

(Y177) and c-Myc protein levels and nuclear localization of ABL1 in PD/ATO-treated mice vs. Imatinib- or vehicle-treated mice (Fig. 7B, C and Supplementary Fig. 10B).

Finally, we also analyzed complete white blood count at different times of treatment and bone marrow cellularity (at the end of treatments) in a non-transplanted mice group ($n = 3$ mice/group of treatments). We did not find any significant changes in total lymphocyte, granulocyte, and monocyte populations counts across the various treatments (Supplementary Table 2) and only a moderate bone marrow hypoplasia in PD/ATO vs. untreated mice (Supplementary Fig. 11 representative data) supporting the fact that the drugs combination is well tolerated at the doses utilized in this *in vivo* study and has no major side effects on normal murine hematopoiesis.

DISCUSSION

In vitro and *in vivo* loss- or gain-of-function approaches on model cell lines and patient-derived leukemic samples were exploited to unveil an unprecedented role of MEK1/2 in sustaining and potentiating the oncogenic and pro-survival effects of BCR::ABL1.

We demonstrate that this phenomenon is exerted through the impairment of the kinase activity of the negative regulator of BCR::ABL1, normal BCR and a concurrent elevation of the levels of activated cytoplasmic non-mutated ABL1.

Consistent with these notions, we demonstrated that blockade of MEK1/2 functions reactivates the anti-oncogenic function of normal BCR kinase as well as converts normal ABL1 kinase from a cytoplasmic oncogenic to a nuclear tumor-suppressive effector thus enhancing the antitumor effects of ATO via activation of BCR-MYC and ABL1-p73 signaling pathways (Fig. 7D).

In this context the main findings of our investigation are:

- (1) MEK1/2 by phosphorylating at Y360 and Y177 residues turns off the tumor suppression functions of BCR [30–34, 44–47] and elevates the oncogenic potential of BCR::ABL1 [33, 34, 37, 38].
- (2) ABL1 cytoplasmic/nuclear ratio and cytoplasmic ABL1^{T735/Y412} phosphorylation are increased and correlated well with the MEK1/2 kinases activity in the leukemic cells, that is consistent with findings demonstrating that cytoplasmic retention drives ABL1 oncogenic function [26, 27].
- (3) Constitutively active forms of MEK increased BCR::ABL1^{Y360/Y177}, BCR^{Y360/Y177} and ABL1^{T735/Y412} phosphorylations and drove resistance to ATO whereas functional disruption of MEK1/2 produced the reversed effects.
- (4) MEK1/2 form a pentameric complex with BCR::ABL1, BCR and ABL1 and contribute to the BCR::ABL1^{Y360/Y177}, BCR^{Y360/Y177}

and ABL1^{T735/Y412} phosphorylations thus enhancing the oncogenic activity of BCR::ABL1 and abrogating the tumor suppression functions of the non-mutated kinases; accordingly, the pharmacological blockade of MEK1/2 promoted dissociation of the pentameric complex and dephosphorylation of the mutated oncogenic and non-mutated counterparts thus leading to the rescue of the tumor suppressive properties of BCR and the nuclear translocation of ABL1.

Our data identify MEK1/2 as the kinases responsible for the specific phosphorylation of ABL1 at T735 residue, which is critical for its cytoplasmic retention [28], thereby indicating that MEK1/2 can influence not only the activity of ABL1 but also its cytoplasmic-nuclear trafficking.

Additionally, our demonstration that the MEK1/2 protein kinases can form a complex with and phosphorylate ABL1 and BCR kinases also in BCR::ABL1-negative leukemic cells, indicates that the functional interplay between these kinases can occur independently of the BCR::ABL1 oncoprotein and are consistent with previous findings showing a functional link between ABL kinases and the Ras-MAPK pathway components in other cell contexts [48].

Further evidence to support this point stems from our previous findings demonstrating that in both BCR::ABL1-positive and -negative leukemia cell lines MEK1/2 inhibition induces the accumulation of tyrosine-phosphorylated endogenous p73 [13], a p53 paralogue that is stabilized and transcriptionally activated at the nuclear level by ABL1-mediated direct phosphorylation at its Tyr99 residue [39], thus indicating that ABL1 can play an important tumor-suppressor role in leukemia.

These findings, taken together with previous studies demonstrating that normal ABL1 kinase not only counteracts the BCR::ABL1 oncogenic functions but also sensitizes CML cells to TKIs [17, 49] suggest that ABL1 could be a crucial therapeutic target to be further explored.

Indeed, by leveraging on the capability of the MEKi to promote normal ABL1 nuclear translocation, the subcellular compartment where it can exert its tumor suppressor functions, we could also demonstrate here that the allosteric activation of nuclear ABL1 kinase activity by DPH significantly potentiates the anti-leukemic effects of the MEKi Mirdametinib on model leukemic cell lines and patient-derived leukemic blasts.

The fact that the efficacy of the PD/DPH combination was detected only in leukemia cells expressing ABL1 supports the concept that DPH exerted its activity by activating ABL1, but not by displacing HSP90 from BCR::ABL1 [17, 50].

Furthermore, we have uncovered a novel role for MEK1/2 in the regulation of the tumor suppression functions of BCR that, in





Fig. 6 Combined treatment with MEK1/2 inhibitor PD0325901 and ATO prolongs survival in mice bearing BCR::ABL1^{T3151}-induced leukemia. **A** Kaplan–Meier survival curves of NOD-SCID mice that had received a syngeneic implantation of Ba/F3p210^{T3151} cells to create BCR::ABL1^{T3151}-induced leukemia and subsequently were alternatively treated with vehicle alone (PBS), PD0325901 (10 mg/kg orally), ATO (3.75 mg/kg intraperitoneally), or Imatinib (50 mg/kg, twice daily, intraperitoneally) or the combination PD + ATO for 3 weeks ($p < 0.0015$, Log-Rank test after Bonferroni correction, PD + ATO-treated animals vs. either treatment alone; $n = 7-8$ per group). Table to the right shows the median survival time and confidence interval for each group of treatment estimated from the Kaplan–Meier survival curve, as evaluated from the first day of treatment until death or sacrifice. **B** Representative gross anatomy and weights of spleens and livers dissected from treated mice compared to those of control mice that did not receive leukemic cell transplantation. (* $p < 0.01$, $^{\circ}p < 0.05$ PD + ATO-treated group vs. either treatment groups, Tukey–Kramer’s test). **C** In situ tissue analysis of representative spleens and livers explanted from leukemic mice that had received vehicle, Imatinib or PD + ATO treatments. Explanted organs were examined by histopathology (hematoxylin-eosin staining), in situ cell proliferation status (immunostaining for Ki-67) and caspase-dependent apoptotic cell death (detection of cleaved caspase-3).



drug-resistant leukemia cells, has been demonstrated to be centered on the degradation of Myc [32, 34], a convergent key node protein for multiple resistance pathways [51–54].

In this context MEK1/2 protein kinases, key elements of the MEK1/2/BCR::ABL1/ABL1/BCR signaling-centered feedback loop discovered in this study, by activating ERK [55] and inactivating BCR critically contribute to the boosting of Myc protein stability [34] and can therefore also represent a valuable therapeutic target for combination therapies on leukemia patients [36].

Based on the present *in vivo* study and our previously reported *in vivo* findings demonstrating only a moderate inhibitory effect of PD/ATO combination on normal hematopoiesis [16] we expect that such a combination therapy will exhibit a safety profile compatible for its clinical use.

Some MEKi, included the one used in our study, have been approved by the US Food and Drug Administration for clinical applications as a monotherapy and/or as a combination therapy with the B-Raf inhibitors in BRAF-mutated melanoma, non-small cell lung carcinoma and neurofibromatosis [56–61]. There is therefore a

Fig. 7 Combined treatment with MEK1/2 inhibitor PD0325901 and ATO activates the tumor suppressor functions of BCR and ABL1 in vivo. **A** Spleens and livers from mice receiving vehicle, Imatinib or PD + ATO treatments were harvested 20 days after leukemia cell inoculation and processed for Western blot analysis to determine the expression of BCR::ABL1 protein and eIF4E, used as loading control. Spleens and livers of non-inoculated control mice as well as lysates from Ba/F3p210^{T3151} cells were examined for comparison. **B** Western blot analysis of phospho-ABL1 (Thr735), ABL1, phospho-BCR (Tyr360), phospho-BCR (Tyr177), BCR, phospho-CrkL (Tyr207), CrkL, c-Myc, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, and Actin on spleens and livers from mice receiving vehicle, Imatinib or PD + ATO treatments. **C** Livers explanted from leukemic mice treated with Imatinib or PD + ATO were examined by immunostaining for ABL1. The majority of leukemic cells in the livers of mice treated with PD + ATO show nuclear staining for ABL1. **D** (i) Under basal conditions MEK1/2 form a complex with and directly phosphorylate BCR, ABL1 and BCR::ABL1 at specific residues thus provoking the loss of BCR's tumor-suppression functions, cytoplasmic retention of ABL1 with oncogenic functions and an enhanced oncogenic activity of BCR::ABL1. In turn, BCR::ABL1 activates MEK1/2 to create a MEK1/2/BCR::ABL1/ABL1/BCR signaling-centered positive feedback loop that stabilizes MYC and disables p73 pro-apoptotic functions to induce drug resistance. (ii) Pharmacological blockade of MEK1/2 disrupts the MEK1/2/BCR::ABL1/ABL1/BCR kinases complex leading to BCR::ABL1^{Y177/Y360}, BCR^{Y177/Y360} and cytoplasmic ABL1^{Y412/T735} dephosphorylation and consequently an attenuated oncogenic BCR::ABL1 signaling, the rescue of the BCR kinase anti-oncogenic functions and the nuclear translocation of ABL1, event that converts the tyrosine kinase from a cytoplasmic oncogenic to a nuclear tumor-suppressive effector. These molecular changes render TKI-resistant leukemic cells vulnerable to ABL1 allosteric activators or arsenic trioxide via activation of ABL1-p73 and BCR-MYC axes.

clear rationale in proposing its clinical experimentation of leukemic patients. In fact, our data indicate that repurposing FDA-approved MEK1/2 inhibitors in combination with ATO may represent a novel alternative strategy for the subset of patients who fail to respond and/or develop resistance to standard-of-care TKIs treatments.

DATA AVAILABILITY

All materials and relevant data described in this manuscript are freely available to any researcher to use for non-commercial purposes.

REFERENCES

- Braun TP, Eide CA, Druker BJ. Response and resistance to BCR::ABL1-targeted therapies. *Cancer Cell*. 2020;37:530–42.
- Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Müller MC, Hochhaus A, et al. The BCR::ABL1T3151 mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. *Haematologica*. 2013;98:1510–6.
- Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17:612–21.
- Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. *Cancer Cell*. 2019;36:431–43.
- Massaro F, Molica M, Breccia M. Ponatinib: a review of efficacy and safety. *Curr Cancer Drug Targets*. 2018;18:847–56.
- Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. *Blood*. 2021;138:2031–41.
- FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia. 2023. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia>.
- ClinicalTrials.gov. Study of efficacy and safety of asciminib in combination with imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). 2023. <https://clinicaltrials.gov/ct2/show/NCT03578367>.
- ClinicalTrials.gov. ABL001 + dasatinib + prednisone in BCR-ABL+ B-ALL or CML. 2023. <https://clinicaltrials.gov/ct2/show/NCT03595917>.
- Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR::ABL1 kinase inhibitors. *Cancer*. 2008;113:985–94.
- Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. *Blood*. 2019;133:1630–43.
- Hoonjan M, Jadhav V, Bhatt P. Arsenic trioxide: insights into its evolution to an anticancer agent. *J Biol Inorg Chem*. 2018;23:313–29.
- Lunghi P, Costanzo A, Levrero M, Bonati A. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. *Blood*. 2004;104:519–25.
- Lunghi P, Tabilio A, Lo-Coco F, Pellicci PG, Bonati A. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. *Leukemia*. 2005;19:234–44.
- Lunghi P, Costanzo A, Salvatore L, Noguera N, Mazzer L, Tabilio A, et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. *Blood*. 2006;107:4549–53.
- Lunghi P, Giuliani N, Mazzer L, Lombardi G, Ricca M, Corradi A, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. *Blood*. 2008;112:2450–62.
- Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. *Blood*. 2016;127:2131–43.
- Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. *Nat Rev Cancer*. 2013;13:559–71.
- Wang JY. The capable ABL: what is its biological function? *Mol Cell Biol*. 2014;34:1188–97.
- La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the BCR::ABL1 kinase inhibitor PD180970 against clinically relevant BCR::ABL1 isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). *Cancer Res*. 2002;62:7149–53.
- Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR::ABL1 positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. *Blood*. 2000;96:1070–9.
- Luong-Gardiol N, Siddiqui I, Pizzitola I, Jeevan-Raj B, Charmoy M, Huang Y, et al. γ -catenin-dependent signals maintain BCR-ABL1+ B cell acute lymphoblastic leukemia. *Cancer Cell*. 2019;35:649–63.e10.
- Bonati A, Carlo-Stella C, Lunghi P, Albertini R, Pinelli S, Migliaccio E, et al. Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias. *Cancer Res*. 2000;60:728–32.
- Hayakawa F, Privalsky ML. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. *Cancer Cell*. 2004;5:389–401.
- Goss VL, Lee KA, Moritz A, Nardone J, Spek EJ, MacNeill J, et al. A common phosphotyrosine signature for the BCR::ABL1 kinase. *Blood*. 2006;107:4888–97.
- Pendergast AM. The Abl family kinases: mechanisms of regulation and signaling. *Adv Cancer Res*. 2002;85:51–100.
- Sirvent A, Benistant C, Roche S. Cytoplasmic signalling by the ABL1 tyrosine kinase in normal and cancer cells. *Biol Cell*. 2008;100:617–31.
- Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of ABL1 in the apoptotic response to DNA damage. *Nat Cell Biol*. 2005;7:278–85.
- Yang J, Campobasso N, Biju MP, Fisher K, Pan XQ, Cottom J, et al. Discovery and characterization of a cell-permeable, small molecule ABL1 kinase activator that binds to the myristoyl binding site. *Chem Biol*. 2011;18:177–86.
- Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N, et al. Inhibition of BCR serine kinase by tyrosine phosphorylation. *Mol Cell Biol*. 1996;16:998–1005.
- Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of BCR serine/threonine kinase. *Oncogene*. 1998;16:141–6.
- Perazzona B, Lin H, Sun T, Wang Y, Arlinghaus R. Kinase domain mutants of BCR enhance BCR::ABL1 oncogenic effects. *Oncogene*. 2008;27:2208–14.
- Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR::ABL1-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. *Cell*. 1993;75:175–85.
- Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T, et al. The c-Myc oncoprotein interacts with BCR. *Curr Biol*. 2003;13:437–41.

35. Yu C, Krystal G, Varticovski L, McKinstry R, Rahmani M, Dent P, et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in BCR/Abl-expressing human leukemia cells. *Cancer Res.* 2002;62:188–99.
36. Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. *Nat Rev Cancer.* 2015;15:577–92.
37. Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. *Cancer Res.* 2007;67:7045–53.
38. He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, Choi JK, et al. The coiled-coil domain and Tyr177 of BCR are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. *Blood.* 2002;99:2957–68.
39. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. *Nature.* 1999;399:806–9.
40. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. *Mol Cell.* 2002;9:175–86.
41. Lunghi P, Costanzo A, Mazzer L, Rizzoli V, Levrero M, Bonati A. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. *Clin Cancer Res.* 2009;15:6495–502.
42. Amin AR, Paul RK, Thakur VS, Agarwal ML. A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. *Cancer Res.* 2007;67:5617–21.
43. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. *J Biol Chem.* 2003;278:18811–6.
44. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. BCR phosphorylated on tyrosine 177 binds Grb2. *Oncogene.* 1997;14:2367–72.
45. Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J, et al. Tyrosine phosphorylation of P160 BCR by P210 BCR::ABL1. *Blood.* 1993;82:1257–63.
46. Lin F, Monaco G, Sun T, Liu J, Lin H, Stephens C, et al. BCR gene expression blocks BCR::ABL1 induced pathogenicity in a mouse model. *Oncogene.* 2001;20:1873–81.
47. Arlinghaus RB. BCR: a negative regulator of the BCR::ABL1 oncoprotein in leukemia. *Oncogene.* 2002;21:8560–7.
48. Jain A, Tripathi R, Turpin CP, Wang C, Plattner R. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. *Oncogene.* 2017;36:4585–96.
49. Virgili A, Koptyra M, Dasgupta Y, Glodkowska-Mrowka E, Stoklosa T, Nacheva EP, et al. Imatinib sensitivity in BCR::ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele. *Cancer Res.* 2011;71:5381–6.
50. Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. *Nat Biotechnol.* 2013;31:630–7.
51. Albajar M, Gómez-Casares MT, Llorca J, Mauleon I, Vaqué JP, Acosta JC, et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. *Mol Cancer Res.* 2011;9:564–76.
52. Giannoudis A, Davies A, Harris RJ, Lucas CM, Pirmohamed M, Clark RE. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. *Leukemia.* 2014;28:1360–3. <https://doi.org/10.1038/leu.2014.38>.
53. Luong-Gardiol N, Siddiqui I, Pizzitola I, Jeevan-Raj B, Charmoy M, Huang Y, et al. γ -catenin-dependent signals maintain BCR::ABL1+ B cell acute lymphoblastic leukemia. *Cancer Cell.* 2019;35:649–63.e10.
54. Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, et al. Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence. *Cell Rep.* 2017;21:2796–812.
55. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. *Genes Dev.* 2000;14:2501–14.
56. Trojaniello C, Festino L, Vanella V, Ascierto PA. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. *Expert Rev Clin Pharm.* 2019;12:259–66.
57. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. *N Engl J Med.* 2017;377:1813–23.
58. Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, et al. NF106: a Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK inhibitor Mirdametnib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. *J Clin Oncol.* 2021;39:797–806.
59. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liskay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med.* 2014;371:1867–76.
60. Rissmann R, Hessel MH, Cohen AF. Vemurafenib/dabrafenib and trametinib. *Br J Clin Pharm.* 2015;80:765–7.
61. Fu H, Gao H, Qi X, Zhao L, Wu D, Bai Y, et al. Aldolase A promotes proliferation and G1/S transition via the EGFR/MAPK pathway in non-small cell lung cancer. *Cancer Commun.* 2018;38:18.

ACKNOWLEDGEMENTS

This work was supported by the Italian Ministry of Health (GR-2016-02363646 to LM), Associazione Italiana per la Ricerca sul Cancro AIRC (IG, Rif 10670, Association for Cancer Research, Milan, Italy; AB) and by Regione Emilia Romagna L.R. 20/2002, GPG/2018/918 to PL).

AUTHOR CONTRIBUTIONS

LM performed cell culture and molecular biology experiments, apoptosis analysis, transfection experiments, analyzed the data, performed statistical analysis and contributed to writing the paper; MA performed cell culture experiments and apoptosis analysis; GL carried out the in vivo experiments; AMC performed histological, immunohistochemical and immunocytochemical analyses; SJ performed histological and immunohistochemical analysis; AC supervised histological and immunohistochemical analysis; MR contributed to in vivo experiments; FA contributed to immunohistochemical analysis; AP discussed the results of in vivo experiments and revised the manuscript; ER, AF, GM, MTS, CV, MB, AR and CG-P provided samples and patients' clinical information; AB provided samples and patients' clinical information and critically revised the manuscript; RP analyzed the data and critically revised the manuscript; PL conceived the idea, designed the research and experiments, performed molecular biology experiments, analyzed and interpreted the data and wrote the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41375-023-01940-x>.

Correspondence and requests for materials should be addressed to Paolo Lunghi.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com